European Journal of Clinical Pharmacology

, Volume 34, Issue 1, pp 109–112

Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans

  • S. R. Bareggi
  • G. Truci
  • S. Leva
  • L. Zecca
  • R. Pirola
  • S. Smirne
Short Communications


Six healthy, fasting volunteers were given single doses of chlordesmethyldiazepam by 1 mg i. v., or as drops or tablets. Chlordesmethyldiazepam and its metabolite, lorazepam, in multiple plasma samples and in urine collected for 120 h after each dose were determined by electron-capture GLC.

Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l · kg−1; elimination half-life, 113 h; total clearance, 0.21 ml · min−1 · kg−1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.

Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops). Bioavailability was 77% for tablets and 79% for drops.

Key words

chlordesmethyldiazepam lorazepam pharmacokinetics i.v./p.o. administration 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Angelis L, Traversa V, Vertua R (1974) Structure activity relationship within the class of 1,4, benzodiazepines: Presence of chlorine and central nervous system activities. Curr Ther Res 16: 324–337Google Scholar
  2. 2.
    Traversa U, De Angelis L, Vertua R (1977) On the hypnogenic and anticonvulsant activities of desmethyldiazepam and chlordesmethyldiazepam: Time-effect relations. J Pharm Pharmacol 29: 504–506Google Scholar
  3. 3.
    Castellani A, Colafelice M, Lorini M, Perbellini D (1979) A single blind, crossover comparison of the anxiolitic activity of chlordesmethyldiazepam: Analysis of single item changes. Clin Ther 2: 343–351Google Scholar
  4. 4.
    Agricola A, Mazzarino M, Agricola R, Urani R, Fresia P (1981) A double-blind, crossover clinical trial of chlordesmethyldiazepam versus lorazepam in neurotic inpatients: Activity on anxiety-depression symptoms. Clin Ther 4: 339–408Google Scholar
  5. 5.
    Lanzoni J, Airoldi L, Marcucci F, Mussini E (1979) Gas chromatographic determination of chlordesmethyldiazepam and lorazepam in rats and mice. J Chromatogr 168: 260–265Google Scholar
  6. 6.
    Dal Bo L, Marcucci F, Mussini E, Perbellini D, Castellani A, Fresia P (1980) Plasma levels of chlordesmethyldiazepam in human. Biopharm Drug Dispos 1: 123–126Google Scholar
  7. 7.
    Bareggi SR, Pirola R, Leva S, Zecca L (1986) Pharmacokinetics of chlordesmethyldiazepam after single-dose oral administration in humans. Eur J Drug Metabol Pharmacokinet 11: 171–174Google Scholar
  8. 8.
    Bareggi SR, Nielsen NP, Leva S, Pirola R, Zecca L, Lorini M (1986) Age-related multiple-dose pharmacokinetics and anxiolytic effects of delorazepam (chlordesmethyldiazepam). Int J Clin Pharmacol Res 6: 309–314Google Scholar
  9. 9.
    Williams TH, Sasso GJ (1979) Novel application of proton nuclear magnetic resonance spectroscopy in the identification of 2-chloronordiazepam in the dog. J Med Chem 22: 436–440Google Scholar
  10. 10.
    De Silva JAF, Bekersky I, Puglisi CV (1973) The determination of 7-chloro-1,3-dihydro-5-(2,chlorphenyl)-2H-1,4-benzodiazepin-2-one (RO-5-3027) and its metabolite (lorazepam) in blood and urine by electron-capture gas-liquid chromatography. J Chromatogr Sci 11: 547–554Google Scholar
  11. 11.
    Zecca L, Ferrario P, Pirola R, Bareggi SR (1987) Analysis of chlordesmethyldiazepam and its metabolites in plasma and urine. J Chromatogr Biomed App 420: 417–429Google Scholar
  12. 12.
    Greenblatt DJ, Franke K, Shader RI (1978) Analysis of lorazepam and its glucuronide metabolite (lorazepam) in blood and urine by electron-capture gasliquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr 146: 311–320Google Scholar
  13. 13.
    Sacchi Landriani G, Guardabasso V, Rocchetti M (1983) NLFIT: A microcomputer program for non-linear fitting. Comput Progr Biomed 16: 35–42Google Scholar
  14. 14.
    Mandelli M, Tognoni G, Garattini S (1978) Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 3: 72–91Google Scholar
  15. 15.
    MacLeod SM, Giles HM, Patzalek G, Thiessen JJ, Sellers EM (1977) Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol 11: 345–349Google Scholar
  16. 16.
    Greenblatt DJ, Shader RI, Weinberger DR, Allen MD, MacLaughlin DS (1978) Effect of a cocktail on diazepam absorption. Psychopharmacology 57: 199–203Google Scholar
  17. 17.
    Greenblatt DJ, Shader RI, Franke K, MacLaughlin DS, Harmatz JS, Allen MD, Werner A, Woo E (1979) Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam. J Pharm Sci 68: 57–63Google Scholar
  18. 18.
    Kaplan SA, Jack ML, Alexander K, Weinfeld RE (1973) Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administration. J Pharm Sci 62: 1789–1804Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • S. R. Bareggi
    • 1
  • G. Truci
    • 2
  • S. Leva
  • L. Zecca
    • 1
  • R. Pirola
    • 1
  • S. Smirne
    • 2
  1. 1.Department of Pharmacology, Medical SchoolUniversita' degli StudiMilanoItaly
  2. 2.Department of Neurology, Istituto Scientifico S. Raffaele, Medical SchoolUniversita' degli StudiMilanoItaly
  3. 3.CNR Center for Muscle WORK PhysiologyMilan

Personalised recommendations